Every article, presentation, spotlight, and news item we've tagged to Therapies and Protocols.
Showing 1–24 of 43
Restore Hyper Wellness is promoting NAD supplementation through IV and intramuscular delivery formats, capitalizing on significant year-over-year increases in consumer search interest for NAD-related therapies. The initiative positions NAD precursors and direct NAD administration as tools for cellular energy optimization, though clinical evidence supporting broad longevity claims remains limited.
Hyperbaric oxygen therapy, traditionally confined to clinical medicine, is being deployed in performance and longevity settings through chambers like ZEUGMA, which operate at pressures enabling oxygen to dissolve into plasma at concentrations far exceeding atmospheric levels. The mechanism addresses tissue oxygen delivery and cellular repair, though evidence for durable benefits in healthy individuals remains under investigation.
Nuchido addresses NAD+ decline through targeted restoration of the salvage pathway rather than simple precursor replacement, supported by randomized controlled human trials demonstrating improvements in inflammation, glycation, and biological age markers. This systems-biology approach represents a maturation of the NAD+ intervention landscape toward mechanistic rather than marketing-driven solutions.
Niagen Bioscience launched Niagen Plus, a telehealth platform delivering prescription-only nicotinamide riboside (Niagen) via at-home subcutaneous injection. The injectable route is positioned to bypass first-pass hepatic metabolism and improve tissue bioavailability compared to oral administration.
Light-activated photodynamic therapy for cutaneous T-cell lymphoma demonstrates a treatment design principle critical to chronic disease management: therapies must be engineered for decades of safe, repeatable use rather than optimized solely for efficacy. For conditions that persist across a lifespan, cumulative toxicity and patient burden become as clinically significant as the primary disease.
Psilocybin demonstrates measurable effects on lifespan and healthspan markers in preclinical models, operating through neuroplasticity pathways and stress-response modulation. The compound's capacity to alter consciousness-linked neural signaling raises questions about its role in longevity pathways previously associated with psychological resilience and systemic stress tolerance.
Renue by Science received recognition for its Total NAD+ Restoration Protocol, a multi-pathway supplement approach designed to address age-related NAD+ decline through enhanced precursor delivery, reduced NAD+ catabolism, improved mitochondrial efficiency, and cellular repair support. NAD+ restoration represents a targeted intervention in the metabolic foundation of cellular aging.
QuantalX Neuroscience has launched Delphi MD, an FDA-cleared non-invasive system that quantifies real-time functional brain network activity using transcranial magnetic stimulation, electroencephalography, and AI analytics. This technology enables clinicians to detect subtle changes in brain function before structural damage or cognitive decline becomes apparent, shifting neurological care from reactive symptom management to preventive assessment.
The FDA granted Breakthrough Device Designation to CorTec's Brain Interchange, a fully implantable wireless brain-computer interface that uses closed-loop neural recording and adaptive stimulation to restore motor function in chronic stroke patients. Early clinical data show meaningful upper-limb recovery in patients whose progression had plateaued under conventional therapy.
AEON Clinic has launched ExoMind, an integrated treatment program combining clinical assessment, neuromodulation, and psychotherapy for treatment-resistant mental health conditions including OCD, ADHD, and PTSD. The program lacks published clinical trial data or specified regulatory clearances, positioning it as a personalized approach to conditions poorly managed by standard therapies.
Psychedelics show promise for cognitive resilience and neural regeneration, but Schedule I classification creates regulatory barriers that prevent clinical investigation of their healthspan applications. Current drug policy frameworks were designed for acute disease endpoints and cannot adequately evaluate interventions targeting age-related decline over extended timeframes.
I-Lumen Scientific received FDA approval to expand enrollment of i-SIGHT2, a clinical trial evaluating non-invasive bioelectric stimulation for intermediate to advanced dry age-related macular degeneration. The therapy aims to restore retinal function through microcurrent stimulation of the retinal pigment epithelium, with U.S. enrollment beginning in late April 2026.
NeuroEM Therapeutics appointed Dr. W. Scott Burgin as Chief Medical Officer to advance its transcranial electromagnetic treatment technology for Alzheimer's disease and cognitive decline. The non-drug approach uses wearable devices to modulate neuronal activity and holds FDA Breakthrough Device designation, positioning it as a potential alternative to pharmaceutical interventions in neurodegeneration.
Cognito Therapeutics and Ochsner Health are partnering to test Spectris, a non-invasive neuromodulation device that delivers synchronized light and sound stimulation to restore gamma oscillations disrupted in Alzheimer's disease. Early evidence shows the approach slows cognitive decline and reduces brain volume loss, with the collaboration designed to evaluate real-world clinical implementation across diverse healthcare settings.
Inbrain Neuroelectronics completed enrollment of a first-in-human trial implanting graphene cortical interfaces in eight patients undergoing neurosurgical tumor resection, demonstrating favorable safety and high-resolution neural signal capture without device-related adverse events. This represents early validation of graphene-based brain-computer interfaces for clinical applications.
NeuroTherapia completed a Phase 2a trial of NTRX-07 in 48 Alzheimer's patients, demonstrating safety and tolerability with no serious adverse events in the treatment group. Exploratory endpoints showed encouraging trends toward cognitive stabilization and favorable biomarkers of neuroinflammation, warranting further investigation in larger trials.
Niagen Bioscience secured a US patent protecting intravenous and injectable formulations of nicotinamide riboside (NR), a NAD+ precursor molecule that declines with age and cellular stress. The patent extends protection through 2044 and positions the company to dominate clinical delivery of NAD+ boosters, a market rapidly expanding across wellness clinics.
Springfield Wellness Center has operated for 25 years using intravenous NAD+ therapy as part of a multimodal protocol for addiction recovery and brain restoration. The clinic's longevity and expansion suggest sustained clinical utility, though the evidence base and mechanistic clarity for NAD+ infusions in longevity contexts remain limited.
Researchers demonstrated that combining NMN supplementation with apigenin—which inhibits NAD+ breakdown—restores muscle function and bone structure in aged mice. This dual approach addresses both supply and preservation of NAD+, a critical coenzyme in cellular energy metabolism and stress resistance.
Researchers demonstrated that combining NAD+ precursor supplementation (NMN) with apigenin, a compound that reduces NAD+ degradation, restores muscle function and bone structure in aged mice. This dual-mechanism approach addresses both NAD+ availability and preservation, with relevance to human aging given prior clinical evidence for NAD+ precursors in metabolic and respiratory function.
NAD+ preservation through dual mechanisms—inhibiting its depletion and enhancing its synthesis—delays cellular senescence while promoting musculoskeletal regeneration. This addresses a central constraint in aging: the body's declining capacity to maintain energy production and tissue repair as NAD+ levels fall with time.
A combination of NMN and apigenin preserves NAD+ levels, activating SIRT3 to suppress cellular senescence and promote differentiation of muscle, bone, and cartilage precursor cells. The regimen also modulates the gut microbiota to increase production of phytosphingosine, an anti-aging metabolite, resulting in improved musculoskeletal function and exercise capacity in aged animals.
NextSense has commercialized in-ear EEG earbuds that move beyond sleep tracking to real-time neural modulation, using closed-loop audio stimulation timed to reinforce slow-wave sleep. This represents a shift from passive measurement to active intervention in a domain central to longevity—though validation across heterogeneous populations and safety protocols remain open questions.
Cleveland Clinic's awarded research uses redox biology—specifically NAD and NADH measurement—to assess metabolic viability of donor organs during the ischemic period before transplantation. This work translates longevity science concepts into actionable clinical tools for organ quality assessment and transplant outcomes.
